Is Actuate Therapeutics Inc (ACTU) a Buy, Sell, or Hold?
Actuate Therapeutics Inc
NASDAQ:ACTU
$1.73 USD
$0.23 (15.33%)
- Volume
- 2.72M
- Average Volume
- 195.69K
- Market Capitalization
- $41.39M
- P/E Ratio
- -1.75
- Dividend Yield
- 0.00%
- Price Target
- $21.00
- Year High
- $9.22
- Year Low
- $1.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel Schmitt |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACTU |
| CUSIP | 005083100 |
| CIK | 0001652935 |
| Web | https://actuatetherapeutics.com |
| Phone | 817 887 8455 |
| Currency | USD |
| Employees | 12 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.80 |
| Quick Ratio | 1.80 |
| Cash Ratio | 1.72 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.83 |
| Price / Cash Flow | -2.11 |
| Price / Book | 10.76 |
Price Target and Rating
| Average Stock Price Forecast | $21.00 |
| High Stock Price Forecast | $21.00 |
| Low Stock Price Forecast | $21.00 |
| Forecast Upside/Downside | -91.76% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.06 |
| Trailing P/E Ratio | -1.75 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-22.23M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -430.93% |
| Return on Assets | -241.68% |
Financials Score
| AltmanZ Score | -28.43 |
| Piotroski Score | 2.00 |
| Working Capital | 3.8M |
| Total Assets | 8.91M |
| Ebit | -21.52M |
| Market Cap | 35.89M |
| Total Liabilities | 5.13M |
Poll Results
About Actuate Therapeutics Inc (NASDAQ:ACTU) Stock
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas. ...
2026-06-09 07:45:00
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma - Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
2026-06-01 07:00:00
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan - Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that two presentations were given at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations featured post-hoc efficacy and biomarker analyses from the randomized Phase 2 study (NCT03678883), along with clinical data from a Phase 2 study conducted at Mass General Brigham Cancer Institute of elraglusib in combination with FOLFIRINOX (FFX) and the TGF-β inhibitor losartan in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
2026-05-11 07:00:00
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026 Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced key initiatives to advance and expand the potential of the elraglusib development program. Actuate is prioritizing the development of the elraglusib oral tablet formulation, which is intended to enhance patient convenience, broaden potential clinical utility, and improve the pharmacokinetic exposure of elraglusib across multiple oncology indications.
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
2026-05-09 11:53:29
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
2026-05-06 08:45:00
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
2026-04-22 07:23:10
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo alone, according to results of a mid-stage trial.
Frequently Asked Questions
-
What is the current Actuate Therapeutics Inc (ACTU) stock price?
-
Actuate Therapeutics Inc(NASDAQ:ACTU) stock price is $1.73 in the last trading session. During the trading session, ACTU stock reached the peak price of $9.22 while $1.16 was the lowest point it dropped to. The percentage change in ACTU stock occurred in the recent session was 15.33% while the dollar amount for the price change in ACTU stock was $0.23.
-
ACTU's industry and sector of operation?
-
The NASDAQ listed ACTU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACTU?
-
Alan Kozikowski | Scientific Founder and Advisor
Andrew Mazar | Co-Founder & Chief Operating Officer
Daniel Schmitt | Chief Executive Officer, President & Director
Paul J. Lytle | Chief Financial Officer
| -
How many employees does ACTU have?
-
Number of ACTU employees currently stands at 12. ACTU operates from 1751 River Run, Fort Worth, TX 76107, US.
-
Link for ACTU official website?
-
Official Website of ACTU is: https://actuatetherapeutics.com
-
How do I contact ACTU?
-
ACTU could be contacted at phone #817 887 8455 and can also be accessed through its website. ACTU operates from 1751 River Run, Fort Worth, TX 76107, US.
-
How many shares of ACTU are traded daily?
-
The average number of ACTU shares traded daily for last 3 months was 195.69K.
-
What is the market cap of ACTU currently?
-
The market value of ACTU currently stands at $41.39M with its latest stock price at $1.73